Summary
GOAL A (completed)- MSLN is the target of many therapeutics being tested in clinical trials but little is understood about the effect of MSLN on PDAC aggressiveness and therapeutic resistance. We have previously found that loss of MSLN impairs the ability of PDAC to colonize the peritoneum and cause metastasis there. MSLN loss from cancer cells impaired the establishment of blood vessels to the new tumor deposits. In FY24and25, we published our data investigating the role of shed MSLN in pancreatic cancer peritoneal metastasis. We found that membrane-bound mesothelin causes tumor cell clusteri
